Associate Professor Joseph (Sefi) Rosenbluh is the Director of the Centre of Functional Genomics and a lab head at the Department of Biochemistry and Molecular Biology at Monash University as well as a Chief Investigator for the Hudson Monash Paediatric Precision Medicine Program. A/Prof Rosenbluh, an early career researcher, has made major contributions in functional cancer genomics and our understanding of how b-catenin signaling promotes cancer.
After completing his PhD at the Hebrew University of Jerusalem, A/Prof Rosenbluh moved to the Broad Institute of Harvard and MIT as a postdoctoral fellow and later as an instructor of medicine. He joined the faculty of Monash University in 2017, and in addition to leading a research lab he directs a new functional genomics platform at Hudson Institute. His recent focus has been on developing CRISPR technologies for loss of function screens, and new approaches such as genetic interaction mapping and high throughput RNA sequencing.
In total, A/Prof Rosenbluh has authored 25 research publications, including 10 in the last five years, many of which are influential publications in journals such as Cell (3 papers), Cell Systems, Nature Genetics and Nature Communications.
Rosenbluh J, Xu H, Harrington W, Gill S, Wang X, Vazquez F, Root DE, Tsherniak A, Hahn WC (2017) Complementary information derived from CRISPR Cas9 mediated gene deletion and suppression Nat Commun 8:15403.
Rosenbluh J, Mercer J, Shrestha Y, Oliver R, Tamayo P, Doench JG, Tirosh I, Piccioni F, Hartenian E, Horn H, Fagbami L, Root DE, Jaffe J, Lage K, Boehm JS, Hahn WC (2016) Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers. Cell Syst 3:302-316.
Kim JW, Botvinnik OB, Abudayyeh O, Birger C, Rosenbluh J, Shrestha Y, Abazeed ME, Hammerman PS, DiCara D, Konieczkowski DJ, Johannessen CM, Liberzon A, Alizad-Rahvar AR, Alexe G, Aguirre A, Ghandi M, Greulich H, Vazquez F, Weir BA, Van Allen EM, Tsherniak A, Shao DD, Zack TI, Noble M, Getz G, Beroukhim R, Garraway LA, Ardakani M, Romualdi C, Sales G, Barbie DA, Boehm JS, Hahn WC, Mesirov JP, Tamayo P (2016) Characterizing genomic alterations in cancer by complementary functional associations. Nat Biotech 34:539-546.
Shao DD, Xue W, Krall, EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim WJ, Zwang Y, Root DE, Jacks T, Hahn WC (2014) KRAS and YAP1 converge to regulate EMT and tumor survival Cell 158:171-184.
Giannakis M, Hodis E, Mu J, Yamauchi M, Rosenbluh J, Cibulskis K, Saksena G, Lawrence MS, Van Allen EM, Hahn WC, Gabriel SB, Lander ES, Getz G, Ogino S, Fuchs CS, Garraway LA (2014) RNF43 is frequently mutated in colorectal and endometrial cancers Nat Genet 46:1264-1266.
Rosenbluh J, Wang X, Hahn WC (2014) Genomic insights into WNT/β-catenin signaling. Trends in Pharmacol Sci 35:103-109.
Hagerstrand D, Tong A, Schumacher SE, Ilic N, Shen RR, Cheung HW, Vazquez F, Shrestha Y, Kim SY, Giacomelli AO, Rosenbluh J, Schinzel AC, Spardy NA, Barbie DA, Mermel CH, Weir BA, Garraway LA, Tamayo P, Mesirov JP, Beroukhim R, Hahn WC (2013) Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discovery 3:1044-1057.
Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak T, Schinzel AC, Shao DD, Schumacher SE, Weir BA, Vazquez F, Cowley GS, Root DE, Mesirov JP, Beroukhim R, Kuo CJ, Goessling W, Hahn WC (2012) β-catenin driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151:1457-1473.
Nijhawan D, Zack TI, Ren Y, Strickland MR, Lamothe R, Schumacher SE, Tsherniak A, Besche HC, Rosenbluh J, Shehata S, Cowley GS, Weir BA, Goldberg AL, Mesirov JP, Root DE, Bhatia SN, Beroukhim R, Hahn WC (2012) Cancer vulnerabilities unveiled by genomic loss. Cell 150:842-854.
Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, De S, Petrini JH, Sung PA, Jasin M, Rosenbluh J, Zwang Y, Weir BA, Hatton C, Ivanova E, Macconaill L, Hanna M, Hahn WC, Lue NF, Reddel RR, Jiao Y, Kinzler K, Vogelstein B, Papadopoulos N, Meeker AK, ALT Starr Cancer Consortium (2012) Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 8:e1002772.
Rosenbluh J, Nijhawan D, Chen Z, Wong KK, Masutomi K, Hahn WC (2011) RMRP Is a Non-Coding RNA Essential for Early Murine Development. PLoS One 6:e26270.
Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, Zhuang L, Rosenbluh J, Chen S, Xiao Y, Shapiro GI, Hahn WC, Chin L (2010) Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U.S.A. 107:11501-11506.